Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer (LYMPHOLUNG)

With the recent approval of Nivolumab for second-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC), immune checkpoint inhibitors are entering the standard of care for lung cancer. Other immune checkpoint inhibitors are under evaluation, both in resectable and non-resectable NSCLC. In order to refine our use of these molecules, comprehensive data on the immune contexture of NSCLC are needed. Moreover,a blood marker of this contexture would allow physicians to monitor the immune status of their patient's tumor and though to evaluate the rightful place of immunotherapy in the multimodal treatment of NSCLC. No such blood marker has been validated so far. The LYMPHOLUNG study investigate the concordance between blood and intratumoral counts of immune cells in resectable stage I to IIIA NSCLC. By the use of 30-marker cytometry, a precise immune profile of NSCLC will be depicted. The prognostic value of the circulating and intra-tumoral T regulator over total lymphocytes ratio for 2-year recurrence-free survival will also be addressed.

Study Overview

• Status: Terminated
• Conditions: Resectable Non-small Lung Cancer
• Intervention / Treatment: Procedure: blood drawn; Procedure: surgical resection of cancer

• Study Type: Interventional
• Enrollment (Actual): 22
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Rouen, France
    • Rouen University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Men and women over 18 years of age
• Histologically- or cytologically- confirmed non-small cell lung cancer diagnostic
• Stage I, II or IIIA NSCLC (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology). Staging must have included an abdominal and thoracic CTscan, a CTscan or MRI of the brain and a 18FDG PETscan
• Subjects for whom a surgical resection is indicated
• Signed written informed consent

Exclusion Criteria:

• - previous, ongoing or planned neo-adjuvant treatment (chemotherapy, targeted therapy, immunotherapy or radiotherapy)
• contraindications to general anesthesia
• contraindication to the planned surgical resection
• history of immunosuppressive disorder
• known history of testing positive for human immunodeficiency virus
• subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 30 days of randomization.
• clinical suspicion of active infection (either acute or chronic)
• severe (hemoglobin < 8.0 g/dL) or symptomatic anemia
• women of childbearing potential must have a negative urine pregnancy test
• women must not be breastfeeding
• prisoners or subjects who are involuntarily incarcerated
• subjects under guardianship

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Patients with resectable non-small cell lung cancer	Procedure: blood drawn; blood drawn; Procedure: surgical resection of cancer

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Level of expression of the T regulator over total lymphocytes count ratio in the blood	Day 1
Level of expression of the T regulator over total lymphocytes count ratio into the tumor	Day 1

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of cell population counts as blood markers for the corresponding population in the tumor	Day 1
Number of patient alive 2 years after resection	2 years

Collaborators and Investigators

• Sponsor: University Hospital, Rouen
• Investigators: Principal Investigator: Bérengère OBSTOY, University Hospital, Rouen

Study record dates

Study Major Dates

• Study Start (Actual): December 14, 2016
• Primary Completion (Actual): February 10, 2020
• Study Completion (Actual): February 10, 2020

Study Registration Dates

• First Submitted: September 14, 2015
• First Submitted That Met QC Criteria: September 15, 2015
• First Posted (Estimated): September 16, 2015

Study Record Updates

• Last Update Posted (Actual): May 4, 2026
• Last Update Submitted That Met QC Criteria: April 28, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms
• Other Study ID Numbers: 2015/080/HP